Multidisciplinarity for the benefit of nano-oncology

November 7th 2018, Amphi Fourier INSA, Toulouse

To see the symposium program: http://rttc-research.com/symposium-program/

To register to the symposium: http://rttc-research.com/symposium-program/registration/





RTTC research:

Our activity is focused on pharmacological targeting of G-protein coupled receptors over-expressed in cancers. We aimed at establishing pharmacological bases for the targeting of receptors in cancers and new targeted therapeutic strategies using targeted nanoparticles. In particular, we recently developed a nanoplatform composed of biocompatible magnetic nanoparticles grafted with gastrin, a peptidic ligand of CCK2 receptors over-expressed in endocrine tumors. When exposed to an alternative magnetic field, this nanoplatform acts as a killing agent of endocrine tumoral cells.


 Mdel RCCK2